Latest Breaking News On - Avidity biosciences daily - Page 9 : comparemela.com

Head-To-Head Analysis: Avidity Biosciences (NASDAQ:RNA) and Generation Bio (NASDAQ:GBIO)

Avidity Biosciences (NASDAQ:RNA – Get Free Report) and Generation Bio (NASDAQ:GBIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of […]

United kingdomUnited statesSan diegoGeneration bio coTorus therapeutics incAvidity biosciences incAvidity biosciencesGet free reportGeneration bioGiven avidity bioscienceDuchenne muscular dystrophyTorus therapeuticsAvidity biosciences dailyNasdaq rnaStock comparisonStock analysis

57,365 Shares in Avidity Biosciences, Inc (NASDAQ:RNA) Purchased by Profund Advisors LLC

Profund Advisors LLC acquired a new position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 57,365 shares of the biotechnology company’s stock, valued at approximately $881,000. Other hedge funds and other institutional investors have also […]

Wells fargo companyAmeritas investment partners incDaiwa securities group incProfund advisorsExchange commissionNeedham companyAvidity biosciences incAvidity biosciences company profileCredit suisse groupBelpointe asset managementAvidity biosciencesFree reportAsset managementInvestment partnersSecurities groupGet free report

Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low at $7 65

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.65 and last traded at $7.70, with a volume of 205688 shares. The stock had previously closed at $7.97. Analysts Set New Price Targets Several brokerages recently commented on […]

Wells fargo companyAncora advisorsBelpointe asset managementRoyal bankAvidity biosciences incCredit suisse groupAmeritas investment partners incNeedham companyAvidity biosciences company profileAvidity biosciencesGet free reportSuisse groupAsset managementInvestment partnersAvidity biosciences dailyNasdaq rna

Avidity Biosciences (NASDAQ:RNA) Price Target Lowered to $23 00 at Chardan Capital

Avidity Biosciences (NASDAQ:RNA) Price Target Lowered to $23 00 at Chardan Capital
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Pricet rowe associates incAvidity biosciences incWells fargo companyBlackrock incAvidity biosciencesFree reportChardan capitalBiosciences trading downGet free reportAvidity biosciences daily

Analysts Set Avidity Biosciences, Inc (NASDAQ:RNA) Price Target at $38 83

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective […]

Charles schwab investment management incWells fargo companyAvidity biosciences incAvidity biosciences company profileMetlife investment managementDimensional fund advisorsVanguard group incAvidity biosciencesGet free reportMarketbeat ratingsWells fargoLife investment managementFund advisorsCharles schwab investment managementSchwab investment managementGet free